logo
919-206-7900
Polarean Imaging plc.'s technology is for research use only

Corporate News

Half-year Report

02 September 2021

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI), announces its unaudited interim results for the six months ended 30 June 2021.

CEO Statement
Statement of Comprehensive Income
Statement of Financial Position
Statement of Changes in Equity
Cash Flow Statement
Download

To view a full version of the results in 
PDF format click here

Highlights

  • Raised £27 million gross proceeds in an oversubscribed financing, including continued support of strategic investors, Bracco Imaging S.p.A and Nukem Isotopes GmbH as well as institutional investor Amati AIM VCT plc, joined by several new UK and US institutional investors
  • Appointment of Chief Financial Officer, Chuck Osborne, to the Board
  • Additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia in Vancouver, Canada
  • Installation of its 9820 Xenon Polariser system for the University of Texas MD Anderson Cancer Center
  • Presentation of data at both the American Thoracic Society (“ATS”) and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conferences
  • Publication of first peer reviewed COVID-19 research by Professor Fergus Gleeson at the University of Oxford
  • Net cash of US$38.2m as of 30 June 2021  

Post-period end

  • Frequent interactions with the FDA as they review the NDA in advance of our target PDUFA goal date of 5 October 2021
  • Preparation for launch of product including recruitment of employees into our sales and marketing organization
  • Planning to broaden the awareness of Polarean technology through exhibitions at CHEST and RSNA 2021 and numerous topical conferences

Richard Hullihen, CEO of Polarean, commented: “During the first half of 2021 the Company raised its largest financing to date with its oversubscribed £27 million gross proceeds financing. We appreciate the continued support from our existing strategic, institutional and retail investors and welcome several new significant institutional investors.  The proceeds from this round are being used to plan and execute the launch of our product in accordance with our current target PDUFA date of 5 October 2021.  We continue to sell new polarisers systems for research use, as the amount of polarised Xenon research continues to increase. We look forward to providing our shareholders with updates regarding further progress and specifically the status of our target PDUFA date of 5 October 2021, and we thank them for their continued support on this exciting journey.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

Enquiries: 

Polarean Imaging plcwww.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive OfficerVia Walbrook PR
Jonathan Allis, Chairman 
  
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)+44 (0)20 7710 7600
Nick Adams / Fred Walsh (Corporate Broking) 
  
Walbrook PRTel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna DunphyMob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application (“NDA”) to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.


CEO Statement

Introduction

The six month period ending 30 June 2021 has seen Polarean make substantial progress towards its goal of seeking FDA approval for the Company's drug-device combination.  As in the normal course, post submission, the Company has responded to the question and answer process with the FDA for our submission, while preparing itself and verifying the preparation of its suppliers and providers.

In January, the Company appointed a new Nominated Advisor and Broker, Stifel Nicolaus Europe Limited, which led to a successful placing, subscription, and open offer which was oversubscribed in every category, including its strategic investors Nukem Isotopes and Bracco. Then in February, Chuck Osborne, the existing CFO, was appointed to the Board in order to further leverage his extensive experience in early-stage life science company management, build out and fund raising.

During challenging times in healthcare and hospital utilization, we continued to take research orders from leading academic centres such as BC Children’s hospital in Vancouver and also to build and deliver systems, completing the installation at MD Anderson Cancer Center in Houston.

Presentation at Medical Conferences and Studies Utilising our Technology

The Company's technology was once again prominent at the ATS and ISMRM virtual conference during May 2021 with over 50 abstracts related to the use of hyperpolarised 129Xe accepted for presentation at the two conferences. The content of our publications and those of our customers, along with our participation is available on our website at www.polarean.com. The user base of our polarisers continues to expand and document the applications of our technology across the spectrum of pulmonary disease.

Importantly, the first peer reviewed article on COVID-19 Long Haul patients visualised using 129Xe have now been published (https://pubs.rsna.org/doi/10.1148/radiol.2021210033). Additional investigator-initiated government research grants are underway to study the use of our technology to assess the long-term effects of COVID-19 infection in patients. 

Results overview 

Group revenues for the first half were US$0.6m (2020: US$0.3m) and were largely derived from the sale of a polariser system to MD Anderson, in contrast to the H1 2020 revenue, which was largely from our collaboration with the University of Cincinnati for work under our SBIR grant, which has now been completed.  We continue to sell our polariser systems on a research-use-only basis to academic institutions in the US, Canada and Europe. Operating expenses for H1 2021 (US$5.5m) increased from H1 2020 (US$3.4m), as Selling and Distribution Expenses (H1 2021 US$1.8m, H1 2020 US $0.4m) increased as we are executing our plans for commercial launch. During H1 2021, the Company recognized Finance Income of US$0.4m due to the strengthening of the British pound, which more than offset the US$0.3m forgivable loan under the US Paycheck Protection Program (“PPP”) we received and recognized as Finance Income in H1 2020. Our overall loss before tax increased from US$3.2m to US$4.9m in the same comparable period, due primarily to the commercial launch preparation expenses. The Company completed a £27m (~$37m) fundraise during H1 2021 via the issue of new equity and as at 30 June 2021 we held US US$38.2m in net cash or cash equivalents.

Post-period end events   

FDA review of NDA

We continue to interact with the FDA as they review our NDA with a target date PDUFA date of 5 October 2021.

Preparation for launch

We continue to prepare for the potential launch of our drug device combination post FDA approval.  In particular, we have been building a sales and marketing organization with the recent recruitment of several sales positions.

Planning for conference exhibitions

We are continuing to increase the awareness of Polarean technology with exhibitions at CHEST in October 2021 and RSNA in December 2021.

Research polarisers

Researchers continue to apply for and receive grants to purchase our polariser systems, most recently BC Children’s Hospital in Vancouver, BC. This system has been delivered and is proceeding to installation. We are in discussions with several research institutions and anticipate additional possible orders during calendar year 2021.

Outlook 

We continue to demonstrate that Polarean's technology has the potential to be of tremendous benefit to patients and a powerful new tool for clinicians in discovering and characterising treatable traits in pulmonary medicine. In addition, our latest new techniques lead us into the field of cardiology and pulmonary vascular disease which is one example of the further potential of our technology. We also look forward to evaluating new uses of our technology in pharmaceutical drug development.

The burden of pulmonary disease in the USA is approximately US$150bn and is widespread and growing, affecting nearly 40 million Americans and 500 million worldwide, with post COVID patients comprising a new segment approaching the scale of asthma. Given the limitations of existing methods of diagnosis and lung disease monitoring, we estimate that there is a significant unmet need for safe, non-invasive, quantitative, and cost-effective image-based diagnosis technology. We believe that our unique medical drug-device combination utilising 129Xe offers the ideal solution for improving pulmonary disease diagnosis.

This is an exciting time for the Company, as we enter the final stages of submitting our NDA and look towards a potential commercial launch before the end of 2021.

Richard Hullihen
Chief Executive Officer

2 September 2021

 

Consolidated unaudited statement of comprehensive income
for the six months ended 30 June 2021

  Unaudited
6 months
ended
30.6.21
US$
 Unaudited
6 months
ended
30.6.20
US$
 Audited
12 months
ended
31.12.20
US$
 Note     
       
Revenue 621,874 327,896 1,056,766
Cost of sales (323,185) (41,387) (346,300)
Gross profit 298,689 286,509 710,466
       
Administrative expenses (2,915,214) (2,724,411) (5,049,246)
Depreciation (81,320) (73,204) (150,224)
Amortisation (375,861) (359,677) (734,058)
Selling and distribution expenses (1,799,324) (351,754) (917,783)
Share based payment expense (367,397) (213,906) (474,716)
Loss from operations (5,240,427) (3,436,443)) (6,615,562)
       
Finance expense (8,261) (9,647)   (19,730)
Finance income 393,392
 267,155
 100,769
Loss on ordinary activities before taxation3(4,855,296) (3,178,935)  (6,534,523)
       
Taxation - - -
Loss and total other comprehensive expense (4,855,296) (3,178,935)  (6,534,523)
Basic and fully diluted loss per share (US$)3(0.026) (0.023)  (0.044)

 

Consolidated unaudited statement of financial position
at 30 June 2021

  Unaudited
As at
30.6.21
US$
 Unaudited
As at
30.6.20
US$
 Audited
As at
31.12.20
US$
AssetsNote     
Non-current assets      
Property, plant and equipment 233,044 312,287 271,264
Intangible assets 2,502,268 3,119,120 2,810,694
Right-of-use asset 116,778 224,414 184,213
Trade and other receivables 5,539 5,539 5,539
  2,857,629 3,661,360 3,271,710
Current assets      
Inventories 1,246,311 950,674 977,924
Trade and other receivables 397,473 522,625 348,067
Cash and cash equivalents 38,197,203 9,190,862 6,282,665
  39,840,987 10,664,161 7,608,656
Total assets 42,698,616 14,325,521 10,880,366
       
Equity      
Share capital4101,545 77,518 78,200
Share premium 59,003,465 23,573,058 23,840,571
Group reorganisation reserve 7,813,337 7,813,337 7,813,337
Share-based payment reserve 2,212,848 1,584,640 1,845,450
Accumulated losses
 
 (29,699,500) (21,488,616) (24,844,204)
Total equity 39,431,695 11,559,936 8,733,354
       
Liabilities      
Non-current liabilities      
Deferred income 219,954 192,817 219,954
Lease liability521,017 149,487 91,609
Contingent consideration 316,000 316,000 316,000
  556,971 658,304 627,563
Current liabilities      
Trade and other payables 2,549,096 1,985,828 1,348,866
Lease liability5137,589 102,213 129,819
Deferred income 23,265 19,239 40,763
  2,709,950 2,107,280 1,519,449
Total equity and liabilities
 
 42,698,616 14,325,521 10,880,366

 

Consolidated unaudited statement of changes in equity
at 30 June 2021

 Share capitalShare premium Group re-organisation Share-based payment reserveAccumulated lossesTotal equity
Balance as at 31 December 2019 (audited)55,77613,659,9127,813,3371,370,734(18,309,681)4,590,078
Loss and total comprehensive income for the period -(3,178,935) (3,178,935) 
Issue of shares 21,742 10,427,537 10,449,279 
Share issue costs-(514,391)---(514,391)
Share-based payments 213,906213,906 
Balance as at 30 June 2020 (unaudited)77,51823,573,0587,813,3371,584,640(21,488,616)11,559,937
Comprehensive income       
Loss and total comprehensive income for the period----(3,355,588)(3,355,588)
Transactions with owners      
Issue of shares682275,836---276,518
Share issue costs-(8,323)---(8,323)
Share-based payments---260,810-260,810
Balance as at 31 December 2020 (audited)78,20023,840,5717,813,3371,845,450(24,844,204)8,733,354
Loss and total comprehensive income for the period----(4,855,296)(4,855,296)
Issue of shares23,34537,260,511---37,283,856
Share issue costs (2,097,617) (2,097,617) 
Share-based payments 367,398367,398
Balance as at 30 June 2021 (unaudited)101,54559,003,4657,813,3372,212,848(29,699,500)39,431,695

 

Consolidated unaudited cash flow statement
for the six months ended 30 June 2021

 Unaudited 6 months ended 30.6.21
US$
Unaudited 6 months ended 30.6.20
US$
Audited 12 months ended
31.12.20
US$
Cash flows from operating activities   
Loss for the period before taxation(4,855,296)(3,178,935)(6,534,522)
Adjustments for non-cash/non-operating items:   
Depreciation of plant and equipment81,32073,204150,224
Amortisation of intangible assets375,861359,677734,058
Share based compensation367,398213,906474,716
Interest paid--19,730
Interest received(470)(92)(100,769)
 (4,031,187)(2,532,240)(5,256,563)
Changes in working capital:   
Increase in inventories(268,387)(396,462)(423,093)
Increase in trade and other receivables(49,406)114,157288,096
Increase/(decrease) in trade and other payables1,310,426189,407(424,714)
Increase/(decrease) in deferred revenue(127,696)(27,085)21,576
Net cash flows used from operating activities(3,166,250) (2,652,223) (5,794,698)
    
Cash flows from investing activities   
Purchase of plant and equipment(43,099)(29,534)(65,531)
Net cash used in investing activities(43,099)(29,534) (65,531)
    
Cash flows from financing activities    
Issue of shares37,283,85610,449,27910,725,797
Cost of issue(2,097,617)(514,391)(522,714)
Interest paid---
Interest received47092100,769
Funds received from PPP loan-22,840-
Principal elements of lease payments(71,083)(56,717)(103,097)
Interest elements of lease payments8,2619,647(19,730)
Net cash generated from financing activities35,123,8879,910,75010,181,025
    
Net increase in cash and equivalents31,914,5387,228,9934,320,796
Cash and equivalents at beginning of period6,282,6651,961,8691,961,869
Cash and equivalents at end of period38,197,203
9,190,862  6,282,665